Effectiveness of sacubitril –valsartan in cancer patients with heart failure

ConclusionsOur experience suggests that sacubitril/valsartan is well tolerated and improves echocardiographic functional and structural parameters, N ‐terminal pro‐B‐type natriuretic peptide levels, and symptomatic status in patients with CTRCD.

Source: ESC Heart Failure - February 6, 2020 Category: Cardiology Authors: Ana Mart ín‐Garcia, Teresa López‐Fernández, Cristina Mitroi, Marinela Chaparro‐Muñoz, Pedro Moliner, Agustin C. Martin‐Garcia, Amparo Martinez‐Monzonis, Antonio Castro, Jose L. Lopez‐Sendon, Pedro L. Sanchez Tags: Short Communication Source Type: research